Upside case
Bull case
—
The bull case requires both strong earnings delivery and the market pricing ROIV more generously than it does today.
Analysis OverviewBuyUpdated May 1, 2026
Roivant Sciences Ltd. (ROIV) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
14
analysts
13 bullish · 0 bearish · 14 covering ROIV
Strong Buy
0
Buy
13
Hold
1
Sell
0
Strong Sell
0
Consensus Target
$33
+15.2% vs today
Scenario Range
— – —
Model bear to bull value window
Coverage
14
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $20.9B
ROIV price targets
Three scenarios for where ROIV stock could go
Current
~$29
Confidence
30 / 100
Updated
May 1, 2026
Market caseClosest to today
Base case
—
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Roivant Sciences Ltd.
ROIV · NASDAQHealthcareBiotechnologyMarch year-end
Roivant Sciences is a biopharmaceutical company that develops and commercializes innovative medicines across multiple therapeutic areas through its network of subsidiary "Vants." It generates revenue primarily from product sales of approved drugs — like its dermatology and immunology treatments — supplemented by licensing deals and research collaborations with larger pharmaceutical partners. Its key advantage is its decentralized "Vant" model, which allows for focused development of individual drug candidates while sharing centralized resources and expertise across the portfolio.
Market Cap
$20.9B
Revenue TTM
$13M
Net Income TTM
-$809M
Net Margin
-6079.9%
ROIV Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
33%Exceptional
vs consensus estimates
Avg EPS Surprise
+14.9%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Last 4 Quarters
EPS beats: 4 of 4Q2 2025
EPS
$-0.22/$-0.26
Revenue
$8M/$54M
Q3 2025
EPS
$-0.18/$-0.25
Revenue
$2M/$7M
Q4 2025
EPS
$-0.28/$-0.32
Revenue
$2M/$6M
Q1 2026
EPS
$-0.24/$-0.30
Revenue
$2M/$5M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q2 2025 | $-0.22/$-0.26 | +16.5% | $8M/$54M | -86.0% |
| Q3 2025 | $-0.18/$-0.25 | +27.9% | $2M/$7M | -70.3% |
| Q4 2025 | $-0.28/$-0.32 | +12.4% | $2M/$6M | -72.0% |
| Q1 2026 | $-0.24/$-0.30 | +19.9% | $2M/$5M | -60.6% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$11M
-17.1% YoY
FY2
$20M
+78.2% YoY
EPS Outlook
FY1
$-0.18
— YoY
FY2
$-0.17
+2.3% YoY
Trailing FCF (TTM)-$767M
FCF Margin: -5761.5%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
ROIV beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
ROIV Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2024
Total disclosed revenue $75M
Product Mix
Latest annual revenue by segment or product family
Product
100.0%
+168.0% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Segment breakdown not available for this company.
Product is the largest disclosed segment at 100.0% of FY 2024 revenue, up 168.0% YoY.
ROIV Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Significantly Overvalued
Fair value est. $3 — implies -90.6% from today's price.
Premium to Fair Value
90.6%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
ROIV
-120.1x
vs
S&P 500
25.2x
576% discount
vs Healthcare Trailing P/E
ROIV
-120.1x
vs
Healthcare
22.1x
642% discount
vs ROIV 5Y Avg P/E
Today
-120.1x
vs
5Y Average
2.0x
6059% discount
Forward PE
—
S&P 500
19.1x
—
Healthcare
19.0x
—
5Y Avg
—
—
Trailing PE
-120.1x
S&P 500
25.2x
-576%
Healthcare
22.1x
-642%
5Y Avg
2.0x
-6059%
PEG Ratio
—
S&P 500
1.75x
—
Healthcare
1.52x
—
5Y Avg
—
—
EV/EBITDA
—
S&P 500
15.3x
—
Healthcare
14.1x
—
5Y Avg
0.6x
—
Price/FCF
—
S&P 500
21.3x
—
Healthcare
18.7x
—
5Y Avg
—
—
Price/Sales
719.6x
S&P 500
3.1x
+22871%
Healthcare
2.8x
+25164%
5Y Avg
—
—
Dividend Yield
—
S&P 500
1.88%
—
Healthcare
1.40%
—
5Y Avg
0.07%
—
| Metric | ROIV | S&P 500 | Healthcare | 5Y Avg ROIV |
|---|---|---|---|---|
| Forward PE | — | 19.1x | 19.0x | — |
| Trailing PE | -120.1x | 25.2x-576% | 22.1x-642% | 2.0x-6059% |
| PEG Ratio | — | 1.75x | 1.52x | — |
| EV/EBITDA | — | 15.3x | 14.1x | 0.6x |
| Price/FCF | — | 21.3x | 18.7x | — |
| Price/Sales | 719.6x | 3.1x+22871% | 2.8x+25164% | — |
| Dividend Yield | — | 1.88% | 1.40% | 0.07% |
ROIV trades above S&P 500 benchmarks on 1 of 2 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolROIV Financial Health
Verdict
Stressed
ROIV returns 6.2% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$13M
Revenue Growth
TTM vs prior year
-56.4%
Gross Margin
Gross profit as a share of revenue
91.2%
Operating Margin
Operating income divided by revenue
-9130.5%
Net Margin
Net income divided by revenue
-6079.9%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$-0.00
Free Cash Flow (TTM)
Cash generation after capex
-$767M
FCF Margin
FCF as share of revenue — the primary cash quality signal
-5761.5%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
-50.4%
ROA
Return on assets, trailing twelve months
-15.5%
Cash & Equivalents
Liquid assets on the balance sheet
$2.7B
Net Cash
Cash exceeds total debt — no net leverage
$2.6B
Debt Serviceability
Net debt as a multiple of annual free cash flow
Net cash ✓
ROE *
Return on equity, trailing twelve months
-16.3%
* Elevated by buyback-compressed equity — compare ROIC (-50.4%) for an undistorted picture of capital efficiency.
Shareholder Returns
How capital is returned to owners
Total shareholder yield
6.2%
Dividend
—
Buyback
6.2%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$1.3B
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
725M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt). ROE marked * where buyback-compressed equity base may inflate the figure.
Open full ratios pageROIV Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 29, 2026
High Risk
Clinical Trial Failures
Roivant Sciences faces substantial risk from potential failures of its drug candidates in clinical trials. The recent miss of batoclimab in Phase 3 TED studies highlights the challenges, as many drugs do not reach the market due to efficacy, safety, or unforeseen side effects.
High Risk
Unprofitability and Cash Burn
Roivant Sciences is deeply unprofitable, with a quarterly cash burn of approximately $188 million. Although the company has around $4.5 billion in cash reserves, its long-term success depends on its drug pipeline delivering results before this cash is depleted.
Medium
Regulatory Hurdles
The biopharmaceutical sector is heavily regulated, and delays or failures in obtaining regulatory approval for drug candidates can significantly impact Roivant's financial performance and timelines.
Medium
Intense Competition
The biopharmaceutical market is highly competitive, with larger pharmaceutical companies and other biotech firms competing for market share. Advancements in competing therapies can increase pressure on Roivant's market positioning.
Medium
Valuation Concerns
Despite significant stock price growth, Roivant may be overvalued based on high Price-to-Sales (P/S) and Price-to-Book (P/B) ratios relative to industry averages. This could indicate that investors expect strong future growth, or that the stock is overvalued.
Lower
Revenue Volatility
Roivant's revenue streams are minimal and can be unpredictable, with recent quarterly revenue showing sharp declines. This volatility provides a negligible offset to the company's massive research and administrative expenses.
Lower
Insider Selling
There has been significant insider selling of ROIV stock over the past three months, which may raise concerns for investors regarding the company's future prospects.
Lower
Technical Indicators
The Moving Average Convergence Divergence (MACD) histogram for ROIV turned negative in late April 2026, potentially signaling a downward trend in the stock price in the coming weeks.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why ROIV Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 29, 2026
Significant Moderna Settlement
Roivant Sciences secured a $2.25 billion global settlement with Moderna regarding COVID-19 vaccine patents and lipid nanoparticle (LNP) technology. This includes an initial payment of $950 million in July 2026 and a potential second payment of $1.3 billion, providing substantial funding for pipeline development.
Promising Pipeline and Drug Candidates
Roivant's pipeline includes promising candidates like Brepocitinib, which has shown significant efficacy in its Phase 3 VALOR study across various conditions. Additionally, IMVT-1402 and Batoclimab are key assets, with IMVT-1402 uniquely positioned in the Graves' disease market.
Strong Analyst Sentiment
Wall Street analysts have a consensus 'Strong Buy' rating for Roivant, with a median price target of $35.00, implying a 25.7% upside from the current stock price. This positive sentiment reflects confidence in the company's future performance.
Vant Model for Drug Development
Roivant's innovative business model utilizes specialized subsidiaries called 'Vants' to focus on specific therapeutic areas, which is expected to accelerate drug development and enhance operational efficiency.
Shareholder-Friendly Actions
The company has initiated a $1 billion buyback program, supported by the recent settlement funds, demonstrating a commitment to returning value to shareholders.
Strong Financial Health
Roivant Sciences boasts a strong balance sheet with over $4.5 billion in cash and zero debt. This financial strength allows the company to fund its pipeline through 2028 without the need for dilutive shareholder offerings.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
ROIV Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$28.82
52W Range Position
92%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$10.58
+172.4% from the low
52-Week High
$30.33
-5.0% from the high
1 Month
+3.37%
3 Month
+11.62%
YTD
+31.4%
1 Year
+160.6%
3Y CAGR
+47.6%
5Y CAGR
+23.8%
10Y CAGR
+10.7%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
ROIV vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 14.4x median
Peer median unavailable
Revenue Growth
-17.1%
vs -16.7% median
-2% below peer median
Net Margin
-6079.9%
vs -302.6% median
-1909% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
ROI ROIV Roivant Sciences Ltd. | $20.9B | — | -17.1% | -6079.9% | Buy | +15.2% |
BHV BHVN Biohaven Ltd. | $1.1B | — | — | — | Buy | +112.1% |
IMV IMVT Immunovant, Inc. | $5.8B | — | — | — | Buy | +58.7% |
KYM KYMR Kymera Therapeutics, Inc. | $7.0B | — | -16.7% | -612.2% | Buy | +35.7% |
PRA PRAX Praxis Precision Medicines, Inc. | $7.6B | — | -25.7% | — | Buy | +61.1% |
ABB ABBV AbbVie Inc. | $362.6B | 14.4x | +7.7% | 6.9% | Buy | +25.2% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
ROIV Dividend and Capital Return
ROIV returns 6.2% annually — null% through dividends and 6.2% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
6.2%
Dividend + buyback return per year
Buyback Yield
6.2%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
1Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$1.3B
Estimated Shares Retired
45M
Approx. Share Reduction
6.2%
Shares Outstanding
Current diluted share count from the screening snapshot
725M
At 6.2%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
FAQ
7 questionsROIV Investor Questions
Common questions answered from live analyst data and company financials.
01Is Roivant Sciences Ltd. (ROIV) stock a buy or sell in 2026?
Roivant Sciences Ltd. (ROIV) is rated Buy by Wall Street analysts as of 2026. Of 14 analysts covering the stock, 13 rate it Buy or Strong Buy, 1 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $33, implying +15.2% from the current price of $29.
02What is the ROIV stock price target for 2026?
The Wall Street consensus price target for ROIV is $33 based on 14 analyst estimates. The high-end target is $40 (+38.8% from today), and the low-end target is $30 (+4.1%).
03Is Roivant Sciences Ltd. (ROIV) stock overvalued in 2026?
Forward earnings data for ROIV is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
04What are the main risks for Roivant Sciences Ltd. (ROIV) stock in 2026?
The primary risks for ROIV in 2026 are: (1) Clinical Trial Failures — Roivant Sciences faces substantial risk from potential failures of its drug candidates in clinical trials. (2) Unprofitability and Cash Burn — Roivant Sciences is deeply unprofitable, with a quarterly cash burn of approximately $188 million. (3) Regulatory Hurdles — The biopharmaceutical sector is heavily regulated, and delays or failures in obtaining regulatory approval for drug candidates can significantly impact Roivant's financial performance and timelines. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Roivant Sciences Ltd.'s revenue and earnings forecast?
Analyst consensus estimates ROIV will report consensus revenue of $11M (-17.1% year-over-year) and EPS of $-0.18 for the upcoming fiscal year. The following year, analysts project $20M in revenue.
06When does Roivant Sciences Ltd. (ROIV) report its next earnings?
A confirmed upcoming earnings date for ROIV is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Roivant Sciences Ltd. generate?
Roivant Sciences Ltd. (ROIV) had a free cash outflow of $767M in free cash flow over the trailing twelve months — a free cash flow margin of 5761.5%. ROIV returns capital to shareholders through and share repurchases ($1.3B TTM).